FDA panel gives cautious backing to Grail test
A US Food and Drug Administration advisory panel gave Grail's Galleri cancer-screening test qualified support. The Financial Times said committee members raised concerns about the test's effectiveness and overall benefits after it failed a UK study earlier this year. Seeking Alpha described the outcome as an endorsement, highlighting the panel's mixed assessment.
Why it matters
The panel's reservations could shape regulatory review of a test intended to detect multiple cancers from one blood sample.
Sources
finite. summarises the reporting above and links to each original. We do not reproduce full articles. Read the sources for complete coverage.
Part of the September 24, 2026 brief.